Xoma diabetes drug fails to meet primary endpoint
Xoma 052, which is being jointly developed by Xoma and Servier, is a monoclonal antibody with the potential to improve the treatment of patients with a wide variety
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.
The result of the study suggested that the economic model evaluated patients in Canada who were treated with Dabigatran Etexilate compared to those treated with warfarin in both